Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bactiguard Holding AB ( ($SE:BACTI.B) ) has provided an update.
Bactiguard ended 2025 with a notably strong fourth quarter, posting a return to operating profit and higher EBITDA despite a full-year decline in revenue driven by currency headwinds and discontinued product lines. License revenues were stable excluding US dollar effects, supported by a strengthened and revised agreement with Zimmer Biomet, expanded regulatory clearances and launches with Becton, Dickinson & Company, and growing early-stage pipelines in cardiology and neurology, while the Hydrocyn aqua wound management range delivered double-digit growth, partially offset by weaker suture sales, leaving the company better positioned to pursue its 2030 growth targets but still forgoing a dividend after a modest full-year loss.
The most recent analyst rating on ($SE:BACTI.B) stock is a Hold with a SEK15.50 price target. To see the full list of analyst forecasts on Bactiguard Holding AB stock, see the SE:BACTI.B Stock Forecast page.
More about Bactiguard Holding AB
Bactiguard Holding AB is a Swedish infection prevention company that develops and licenses proprietary coating technologies for medical devices, working with leading MedTech partners in areas such as orthopedics, cardiology, and neurology. The company also sells its own wound management products, notably the Hydrocyn aqua line, with a focus on reducing healthcare-associated infections in markets including Europe and India.
Average Trading Volume: 31,923
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK520.4M
For an in-depth examination of BACTI.B stock, go to TipRanks’ Overview page.